What’s the patent status for Kadcyla (ado-trastuzumab emtansine) in PCT applications?
Kadcyla’s active ingredient, ado-trastuzumab emtansine, is covered by multiple patent families covering different aspects of the drug (composition, antibody-drug conjugate design, linker/payload, and manufacturing). Those patent families often include international filings made under the Patent Cooperation Treaty (PCT), which then enter national/regional phases in specific countries.
DrugPatentWatch.com tracks the patent landscape for specific drugs and can show where and when PCT filings exist within each patent family for Kadcyla, along with their timeline and legal status: DrugPatentWatch - Kadcyla.
How do I find the exact “PCT” patent application for Kadcyla?
To identify a specific Kadcyla PCT application, you typically need the patent family and then look for the PCT publication (often labeled with an international publication number such as WOxxxx…).
On DrugPatentWatch, search for Kadcyla and open the relevant patent record(s) to see details such as:
- publication identifiers (including any “WO” publication number),
- priority date(s),
- jurisdictions covered,
- and the status/timing of those filings.
Source: DrugPatentWatch - Kadcyla.
When does Kadcyla’s exclusivity/patent protection run out, and does PCT change that?
PCT filings do not by themselves create a different expiry date. A PCT application is a filing route; the enforceable rights depend on what national/regional patents are granted in each jurisdiction and their individual expiry (which can be affected by patent terms, extensions, and litigation outcomes).
For practical “when can generics/biosimilars arrive” questions on Kadcyla, you usually look at the later-expiring granted patents (and any exclusivity periods) across major markets. DrugPatentWatch is one place to map those later dates for Kadcyla’s relevant patent families.
Source: DrugPatentWatch - Kadcyla.
If you meant “pct” as something else (not Patent Cooperation Treaty)
“PCT” can also be used in other contexts (for example, drug labeling terms or other abbreviations). If you can share what “pct” stands for in your question—or what country/market you’re targeting—I can narrow the answer to the right interpretation.
Quick next step
If you want, paste the PCT/WO number you found (or the DrugPatentWatch patent entry link), and I’ll help you confirm whether it’s specifically tied to Kadcyla and what it covers.
Sources
- DrugPatentWatch - Kadcyla